Loading...
The quadrivalent human papillomavirus (HPV) vaccine — which targets HPV types 6, 11, 16, and 18 — gained FDA approval in June 2006 based on initial results of two worldwide, industry-sponsored, blinded, placebo-controlled phase III trials. Both trials are ongoing, and investigators now report updated findings about this three-dose vaccine’s efficacy in preventing genital warts and cervical lesions.
The first trial included more than 5000 women (age range, 16–24). After a mean follow-up of 3 years, the vaccine was demonstrated to be 100% effective in preventing vaccine-type anogenital warts, cervical intraepithelial neoplasia (CIN) grades 1–3, and cervical adenocarcinoma in situ among recipients with no evidence of prior infection. Results of…